FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007150198> ?p ?o ?g. }

• W2007150198 endingPage "125" @default.
• W2007150198 startingPage "121" @default.
• W2007150198 abstract "In 1933 Auguste Loubatières started to work at the Physiological Laboratory of the Montpellier Medical School, famous for the scientific work of Emmanuel Hédon and then Louis Hédon on experimental diabetes mellitus. Auguste Loubatières was particularly interested in the study of a new preparation of long-lasting insulin (insulin-protamine-zinc: IPZ) in the totally pancreatectomized dog. In 1938, he observed that high doses of IPZ induced a severe and protracted hypoglycemia entailing convulsive attacks and even irreversible coma. The story of hypoglycemic sulfonamides started in France in spring 1942. During the second world war, because of the food shortage in Montpellier, a lot of people ate rotting food or even food contaminated with bacteria, such as shellfish. Many cases of thyphoid fever were diagnosed and treated by Marcel Janbon at the Clinic of the Montpellier Medical School with a new sulfonamide (VK 57 or 2254 RP). Adverse reactions were observed: in some patients, convulsions and even prolonged coma occurred; in some others a major drop in blood glucose was observed. M. Janbon informed the physiologists about these observations questioning them for an interpretation. A. Loubatières was particularly interested and immediately undertook animal trials. On June 13, 1942, he observed that repeated oral administration of 2254 RP in the normal fasting conscious dog induced a progressive, marked and long-lasting decrease in glycemia. He continued his experiments and definitively established the hypoglycemic effect of this sulfonamide. However the mechanism of action remained to be established. The pattern of some graphs reminded him that of some others he could previously observe in the study with IPZ; it occurred to him that 2254 RP could lower the blood glucose concentration by stimulating insulin secretion. He had then to establish the validity of his hypothesis. From 1942 to 1946, A. Loubatières performed a systematic study of the effects of 2254 RP and structural analogs and investigated the mechanism involved in the hypoglycemia. These results are reported in his Doctorat ès-Sciences thesis (1946). He observed that 2254 RP was ineffective on glycemia in totally pancreatectomized dogs but was effective in partially pancreatectomized ones. The hypoglycemic effect in normal dog was dependent on the plasma sulfonamide concentration; this effect appeared whatever the route of administration and was unaffected by vagotomy. Furthermore, Loubatières performed cross-circulation experiments. In these experiments, the pancreatico-duodenal vein of a normal dog was anastomosed to the jugular vein of a receiver dog made diabetic by alloxan; in this case, the injection of 2254 RP into the donor induced a decrease in blood glucose levels in the receiver. In early 1946, Auguste Loubatières proposed that the hypoglycemic property of 2254 RP was due to its ability to stimulate insulin secretion through a direct action on pancreatic islets; he wrote in his thesis A notre avis, le para-amino-benzène-sulfamido-isopropylthiodiazol (2254 RP) est donc un corps essentiellement insulino-sécréteur; son action s'exerce directement sur les îlots de Langerhans. He also proposed to use such hypoglycemic sulfonamides in certain forms of diabetes que l'on peut qualifier de fonctionnels et qui sont la conséquence d'une paresse des mécanismes insulino-sécréteurs. In 1992, Jean-Claude Henquin demonstrated that the sequence of events triggered by 2254 RP at the level of islet beta-cells was similar to that induced by sulfonylureas of the first or second generation. Thus, the 2254 RP, proposed by Auguste Loubatières in the treatment of certain forms of diabetes, was the first of oral hypoglycemic sulfonamides currently used in the treatment of type 2 diabetes mellitus." @default.
• W2007150198 created "2016-06-24" @default.
• W2007150198 creator A5052874352 @default.
• W2007150198 date "2007-01-01" @default.
• W2007150198 modified "2023-10-06" @default.
• W2007150198 title "La découverte des sulfamides hypoglycémiants" @default.
• W2007150198 doi "https://doi.org/10.1051/jbio:2007014" @default.
• W2007150198 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17978743" @default.
• W2007150198 hasPublicationYear "2007" @default.
• W2007150198 type Work @default.
• W2007150198 sameAs 2007150198 @default.
• W2007150198 citedByCount "25" @default.
• W2007150198 countsByYear W20071501982014 @default.
• W2007150198 countsByYear W20071501982015 @default.
• W2007150198 countsByYear W20071501982016 @default.
• W2007150198 countsByYear W20071501982018 @default.
• W2007150198 countsByYear W20071501982019 @default.
• W2007150198 countsByYear W20071501982020 @default.
• W2007150198 countsByYear W20071501982021 @default.
• W2007150198 countsByYear W20071501982022 @default.
• W2007150198 crossrefType "journal-article" @default.
• W2007150198 hasAuthorship W2007150198A5052874352 @default.
• W2007150198 hasBestOaLocation W20071501981 @default.
• W2007150198 hasConcept C100136789 @default.
• W2007150198 hasConcept C120665830 @default.
• W2007150198 hasConcept C121332964 @default.
• W2007150198 hasConcept C126322002 @default.
• W2007150198 hasConcept C134018914 @default.
• W2007150198 hasConcept C187212893 @default.
• W2007150198 hasConcept C2779306644 @default.
• W2007150198 hasConcept C2780668416 @default.
• W2007150198 hasConcept C555293320 @default.
• W2007150198 hasConcept C71924100 @default.
• W2007150198 hasConceptScore W2007150198C100136789 @default.
• W2007150198 hasConceptScore W2007150198C120665830 @default.
• W2007150198 hasConceptScore W2007150198C121332964 @default.
• W2007150198 hasConceptScore W2007150198C126322002 @default.
• W2007150198 hasConceptScore W2007150198C134018914 @default.
• W2007150198 hasConceptScore W2007150198C187212893 @default.
• W2007150198 hasConceptScore W2007150198C2779306644 @default.
• W2007150198 hasConceptScore W2007150198C2780668416 @default.
• W2007150198 hasConceptScore W2007150198C555293320 @default.
• W2007150198 hasConceptScore W2007150198C71924100 @default.
• W2007150198 hasIssue "2" @default.
• W2007150198 hasLocation W20071501981 @default.
• W2007150198 hasLocation W20071501982 @default.
• W2007150198 hasOpenAccess W2007150198 @default.
• W2007150198 hasPrimaryLocation W20071501981 @default.
• W2007150198 hasRelatedWork W2045993936 @default.
• W2007150198 hasRelatedWork W2055794815 @default.
• W2007150198 hasRelatedWork W2057262151 @default.
• W2007150198 hasRelatedWork W2057434408 @default.
• W2007150198 hasRelatedWork W2068655959 @default.
• W2007150198 hasRelatedWork W2076754594 @default.
• W2007150198 hasRelatedWork W2083753940 @default.
• W2007150198 hasRelatedWork W2110641431 @default.
• W2007150198 hasRelatedWork W2112253737 @default.
• W2007150198 hasRelatedWork W2121663374 @default.
• W2007150198 hasVolume "201" @default.
• W2007150198 isParatext "false" @default.
• W2007150198 isRetracted "false" @default.
• W2007150198 magId "2007150198" @default.
• W2007150198 workType "article" @default.